肝活检在ANA阳性伴轻度肝酶升高患者中的诊断价值
该回顾性研究分析313例因不明原因肝酶升高接受肝活检的成人,发现ANA阳性且ALT<101 U/L的患者中仅9%组织学符合自身免疫性肝炎,仅3.8%需长期免疫抑制,提示此类患者可安全推迟肝活检。
要点
- ANA阳性且ALT<101 U/L者仅9%组织学符合AIH,3.8%需长期免疫抑制。
- 该组需免疫抑制的3例中2例已有代偿性肝硬化。
- 对ANA阳性、非肝硬化、ALT<101 U/L且无其他病因者,可安全推迟肝活检。
核心结论
- ANA阳性、非肝硬化且ALT<101 U/L、无其他可疑病因的患者,肝活检额外诊断价值有限,可安全推迟。
研究设计与样本
- 回顾性分析2019至2024年海德堡大学医院313例因不明原因肝酶升高(含疑似自身免疫性肝炎)行经皮肝活检的成人。
- 组织学按2022年国际自身免疫性肝炎病理学组共识建议分类。
- 排除恶性肿瘤、移植后活检或数据不完整者。
主要发现
- 中位年龄49岁,女性占55.3%,ALT和AST中位数分别为161 U/L和106 U/L。
- ANA阳性占61.3%,ANA阳性者22.4%组织学符合自身免疫性肝炎,ANA阴性者15.7%符合。
- ANA阳性且ALT<101 U/L者中仅9%组织学符合自身免疫性肝炎,3.8%(3例)需长期免疫抑制,其中2例有代偿性肝硬化。
关键数值与推荐
- ANA阳性且ALT<101 U/L患者中,组织学符合自身免疫性肝炎者占9%。
- 同一组中需长期免疫抑制者占3.8%(3例),其中2例为代偿性肝硬化。
临床怎么用
- 对ANA阳性、非肝硬化、ALT<101 U/L且无其他可疑病因者,可安全推迟肝活检。
- 肝活检应保留给肝酶较高或鉴别诊断不明确者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Abnormal liver enzyme elevations with positive antinuclear antibodies (ANA) frequently prompt investigation for autoimmune hepatitis after common causes such as viral hepatitis or drug-induced liver injury have been excluded. Current guidelines recommend liver biopsy for suspected autoimmune hepatitis, but its utility in patients with only mild transaminase elevation remains uncertain. This study evaluated the diagnostic yield of liver biopsy in such patients, particularly when alanine aminotransferase is below 101 U/L. METHODS: We retrospectively analysed 313 adults who underwent percutaneous liver biopsy at the University Hospital Heidelberg between 2019 and 2024 for unexplained liver enzyme elevation including suspected autoimmune hepatitis. Clinical data were extracted, and histology was classified according to the 2022 International Autoimmune Hepatitis Pathology Group consensus recommendations. Patients with malignancy, post-transplant biopsy, or incomplete data were excluded. RESULTS: The median age was 49 years; 55.3% were female. Median alanine aminotransferase and aspartate aminotransferase were 161 U/L and 106 U/L, respectively. Antinuclear antibodies were positive in 61.3% of cases. 22.4% of antinuclear antibody positive and 15.7% of antinuclear antibody negative patients had autoimmune hepatitis compatible histology. Among patients with positive antinuclear antibodies and alanine aminotransferase < 101 U/L, only 9% showed autoimmune hepatitis compatible histology and 3.8% (three patients) required long-term immunosuppression. Two of these three patients had compensated liver cirrhosis. CONCLUSIONS: Liver biopsy provides limited additional diagnostic value in ANA-positive, non-cirrhotic patients with alanine aminotransferase < 101 U/L and no alternative suspected aetiology. In such cases, the procedure can be safely deferred, reserving biopsy for higher enzyme elevations or unclear differential diagnoses.
引用
- Niazi DMA, Charbel A, Pfeiffenberger J, et al. Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation. Aliment Pharmacol Ther. 2026. PMID: 41954042. doi:10.1111/apt.70665
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。